Cite
HARVARD Citation
Yerushalmi, R. et al. (n.d.). A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. Breast. pp. S12-. [Online].